Skip to main content
. Author manuscript; available in PMC: 2010 May 12.
Published in final edited form as: Pediatr Infect Dis J. 2010 May;29(5):391–396. doi: 10.1097/INF.0b013e3181c38f3b

TABLE 1.

Study Participants With Adverse Events Occurring Within 42 d After Immunization, by CD4% Stratum at Screening (N = 319)

Adverse Event (AE) CD4% Stratum
at Screening
Overall
(n = 319)
<15%
(n = 39)
15%–24%
(n = 127)
≥25%
(n = 153)
Death or GBS 0 0 0 0
Laboratory AEs, grade ≥3 2 (5.2%) 0 0 2 (0.6%)
Signs and symptoms AEs, grade ≥3 1 (2.6%) 3 (2.4%) 1 (0.7%) 5 (1.6%)
Any of above 3 (7.9%) 3 (2.4%) 1 (0.7%) 7 (2.2%)
Any of above, possibly related to MCV4 vaccine 0 0 0 0